Vertex Ventures HC Announces Two New Hires

Vertex Ventures HC has announces the following additions to its team:

• George Golumbeski has joined the firm as an Executive Advisor. George brings extensive experience in the biopharmaceutical space. He has served as: Executive Vice President of Business Development for Celgene; Vice President of Business Development, Licensing, and Strategy for Novartis; Vice President of R&D Business Development for Elan Pharmaceuticals; and Vice President of Corporate Development for Schwarz Pharma. He currently serves on the Board of Directors/Trustees of Acceleron Pharma, Enanta Pharmaceuticals, the Keck Graduate Institute, and the National Audubon Society.

• Faheem Hasnain has joined the firm as an Executive Advisor. He is currently Co-Founder and Executive Chairman of Gossamer Bio. Some notable roles throughout his career include: President, Chief Executive Officer and a Director of Receptos; President and Chief Executive Officer and a Director of Facet Biotech Corporation; President, Chief Executive Officer and a Director of PDL BioPharma; and Executive Vice President for Oncology/Rheumatology for Biogen. Faheem serves as Chairman of the Board of Directors for Mirati Therapeutics, Aspen Neuroscience, and SENTE. He is also Lead Independent Director of Kura Oncology.

Vertex Ventures HC is a healthcare and life sciences VC fund investing across medical devices, biotech, diagnostics and digital health services. The San Francisco, CA-based firm currently has $300 million in assets under management.